RecruitingPhase 1NCT06585449

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Studying Huntington's Disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alnylam Pharmaceuticals
Principal Investigator
Medical Director
Alnylam Pharmaceuticals
Intervention
ALN-HTT02(drug)
Enrollment
66 enrolled
Eligibility
25-70 years · All sexes
Timeline
20242028

Study locations (19)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06585449 on ClinicalTrials.gov

Other trials for Huntington's Disease

Additional recruiting or active studies for the same condition.

See all trials for Huntington's Disease

← Back to all trials